QQQ   426.91 (+0.25%)
AAPL   167.63 (-0.22%)
MSFT   412.94 (+0.27%)
META   497.50 (+0.67%)
GOOGL   155.70 (+0.15%)
AMZN   181.90 (+0.34%)
TSLA   151.57 (-2.50%)
NVDA   848.00 (+0.91%)
AMD   154.40 (+0.25%)
NIO   3.90 (-0.26%)
BABA   69.10 (+0.41%)
T   16.12 (+0.19%)
F   12.06 (+0.17%)
MU   117.30 (+0.83%)
GE   155.77 (+0.06%)
CGC   6.50 (+0.15%)
DIS   112.90 (-0.04%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.47 (+0.33%)
XOM   118.80 (+0.14%)
QQQ   426.91 (+0.25%)
AAPL   167.63 (-0.22%)
MSFT   412.94 (+0.27%)
META   497.50 (+0.67%)
GOOGL   155.70 (+0.15%)
AMZN   181.90 (+0.34%)
TSLA   151.57 (-2.50%)
NVDA   848.00 (+0.91%)
AMD   154.40 (+0.25%)
NIO   3.90 (-0.26%)
BABA   69.10 (+0.41%)
T   16.12 (+0.19%)
F   12.06 (+0.17%)
MU   117.30 (+0.83%)
GE   155.77 (+0.06%)
CGC   6.50 (+0.15%)
DIS   112.90 (-0.04%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.47 (+0.33%)
XOM   118.80 (+0.14%)
QQQ   426.91 (+0.25%)
AAPL   167.63 (-0.22%)
MSFT   412.94 (+0.27%)
META   497.50 (+0.67%)
GOOGL   155.70 (+0.15%)
AMZN   181.90 (+0.34%)
TSLA   151.57 (-2.50%)
NVDA   848.00 (+0.91%)
AMD   154.40 (+0.25%)
NIO   3.90 (-0.26%)
BABA   69.10 (+0.41%)
T   16.12 (+0.19%)
F   12.06 (+0.17%)
MU   117.30 (+0.83%)
GE   155.77 (+0.06%)
CGC   6.50 (+0.15%)
DIS   112.90 (-0.04%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.47 (+0.33%)
XOM   118.80 (+0.14%)
QQQ   426.91 (+0.25%)
AAPL   167.63 (-0.22%)
MSFT   412.94 (+0.27%)
META   497.50 (+0.67%)
GOOGL   155.70 (+0.15%)
AMZN   181.90 (+0.34%)
TSLA   151.57 (-2.50%)
NVDA   848.00 (+0.91%)
AMD   154.40 (+0.25%)
NIO   3.90 (-0.26%)
BABA   69.10 (+0.41%)
T   16.12 (+0.19%)
F   12.06 (+0.17%)
MU   117.30 (+0.83%)
GE   155.77 (+0.06%)
CGC   6.50 (+0.15%)
DIS   112.90 (-0.04%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.47 (+0.33%)
XOM   118.80 (+0.14%)
NASDAQ:ADMP

Adamis Pharmaceuticals (ADMP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.77
$3.99
52-Week Range
N/A
Volume
119,800 shs
Average Volume
811,695 shs
Market Capitalization
$7.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ADMP stock logo

About Adamis Pharmaceuticals Stock (NASDAQ:ADMP)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

ADMP Stock News Headlines

DMK Pharmaceuticals Corp DMK
3 Sub-$10 Stocks to Buy for 2024
Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.
3 Sub-$10 Stocks to Buy for 2024
Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.
Adamis Pharmaceuticals (NASDAQ: ADMP)
Q1 2023 Adamis Pharmaceuticals Corp Earnings Call
See More Headlines
Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/31/2022
Today
4/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMP
Fax
N/A
Employees
11
Year Founded
2006

Profitability

Net Income
$-26,480,000.00
Net Margins
-502.73%
Pretax Margin
-471.80%

Debt

Sales & Book Value

Annual Sales
$4.76 million
Book Value
($1.26) per share

Miscellaneous

Free Float
9,237,000
Market Cap
$7.26 million
Optionable
Optionable
Beta
1.27

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. David J. Marguglio (Age 53)
    Co-Founder, Interim CFO. Pres & COO
    Comp: $526.35k
  • Dr. Ebrahim Versi M.D. (Age 70)
    Ph.D., CEO & Chair of the Board
  • Ms. Jennifer C. Suski
    Sr. Director of Marketing
  • Mr. Eddie Wabern Glover (Age 73)
    Chief Exec. Officer of US Compounding Inc
  • Mr. Robert B. Rothermel (Age 79)
    Consultant

ADMP Stock Analysis - Frequently Asked Questions

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) announced its earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) EPS for the quarter, missing analysts' consensus estimates of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative net margin of 502.73% and a negative trailing twelve-month return on equity of 420.53%. During the same period in the prior year, the company posted ($11.20) EPS.

When did Adamis Pharmaceuticals' stock split?

Shares of Adamis Pharmaceuticals reverse split before market open on Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

This page (NASDAQ:ADMP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners